Corvus Pharma reports Q3 financials, finishes enrollment in atopic dermatitis trial, 200 mg BID dose with 8-wk treatment; data in Jan.

Unusual Whales
2025.11.04 21:05
Enrollment for the extension cohort 4 of the Phase 1 trial for soquelitinib in atopic dermatitis has been finalized. This cohort involves a dosage of 200 mg BID with an 8-week treatment timeframe. The data from this trial is expected to be disclosed in January.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer